LINE-1 reverse transcriptase is an endogenous reverse transcriptase encoded by repetitive sequences in the human genome.
eRTs convert RNA into DNA in the cytosol, triggering a viral mimicry response via nucleic acid-sensors, such as cGAS, resulting in activation of Type 1 interferon and NFκB pathways.
Since excess activation of these pathways can lead to autoimmune disease, eRT inhibitors have great potential to improve pathological outcomes.
Through rational structure-based drug design, Rome identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase.
The data show that Rome's compound inhibited a Type 1 interferon response in multiple in vivo and in vitro models of autoimmune disease.
Rome Therapeutics is developing novel therapies for cancer and autoimmune diseases by illuminating the role of the dark genome in human health and disease.
Leveraging the company's unprecedented data sciences platform, Rome has built a deep pipeline of therapies targeting the dark genome.
Rome is based in Boston, Mass.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial